CYCC - Cyclacel gets dosing underway in phase 1/2 oral fadraciclib study

Cyclacel Pharmaceuticals (NASDAQ:CYCC) announces the dosing of the first patient in the company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS). The Phase 1/2 registration-directed trial, designated CYC065-102, uses a streamlined design and will first determine the recommended Phase 2 dose (RP2D) for single-agent, oral fadraciclib. Once RP2D has been established, the trial will immediately enter into proof-of-concept, cohort stage, using a Simon 2-stage design, where fadraciclib will be administered to patients in up to seven cohorts relevant to the drug’s mechanism of action.

For further details see:

Cyclacel gets dosing underway in phase 1/2 oral fadraciclib study